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Abstract
We employed second-harmonic generation (SHG) imaging and the zebrafish model to investigate the myopathy caused by
statin in vivo with emphasis on the altered microstructures of the muscle sarcomere, the fundamental contractile element of
muscles. This approach derives an advantage of SHG imaging to observe the striated skeletal muscle of living zebrafish
based on signals produced mainly from the thick myosin filament of sarcomeres without employing exogenous labels, and
eliminates concern about the distortion of muscle structures caused by sample preparation in conventional histological
examination. The treatment with statin caused a significantly shortened sarcomere relative to an untreated control
(1.7360.09 mm vs 1.9160.08 mm, P,0.05) while the morphological integrity of the muscle fibers remained largely intact.
Mechanistic tests indicated that this microstructural disorder was associated with the biosynthetic pathway of cholesterol,
or, specifically, with the impaired production of mevalonate by statins. This microstructural disorder exhibited a strong
dependence on both the dosage and the duration of treatment, indicating a possibility to assess the severity of muscle
injury according to the altered length of the sarcomeres. In contrast to a conventional assessment of muscle injury using
clinical biomarkers in blood, such as creatine kinase that is released from only disrupted myocytes, the ability to determine
microstructural modification of sarcomeres allows diagnosis of muscle injury before an onset of conventional clinical
symptoms. In light of the increasing prevalence of the incidence of muscle injuries caused by new therapies, our work
consolidates the combined use of the zebrafish and SHG imaging as an effective and sensitive means to evaluate the safety
profile of new therapeutic targets in vivo.
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Introduction
Statins are among the most widely prescribed medications with
proven records in decreasing the cardiovascular morbidity and
mortality of patients with or without coronary artery diseases; the
number of patients indicated to receive long-term statins
continually increases [1,2]. Statins serve the above role through
effectively decreasing the level of low-density lipoprotein choles-
terol by inhibiting competitively 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes
the endogenous synthesis of cholesterol in liver [3]. Although
statins are well tolerated by most patients, they can produce
myopathy in some patients with varied clinical symptoms ranging
from mild myalgia or muscle weakness, to fatal rhabdomyolysis
[4,5]. The deleterious muscle manifestations of statins have
received considerable attention, especially after a global with-
drawal of cerivastatin in 2001 that claimed about 100 deaths
associated with rhabdomyolysis [6]. Despite extensive effort, a
controversy about the pathogenesis of statin-induced myopathy
remains largely unresolved [7,8,9]. Most clinical trials associate the
myotoxic effect of statins with a circulating level of creatine
phosphokinase (CPK) greater than five to ten times the normal
value, but this biomarker does not invariably correlate with clinical
symptoms of myopathy because an elevated CPK value can be
associated with several diseases; the clinical symptom of myopathy
has been difficult to evaluate and can be subjective from patient to
patient [10,11]. Because the enzyme is unstable, whereby its
circulating level in blood can be apparently lost before blood
sampling, the use of CPK as a reliable biomarker of muscle disease
is questioned [12,13]. Identification of a reliable and specific index
that can assess objectively the symptoms or the severity of
myopathy is important for an exploration of the pathogenesis and
for the development of effective therapies against the disease.
Second-harmonic generation (SHG) is a nonlinear optical
process that involves interaction of light with polarizable materials
lacking centrosymmetry [14,15]. It is intrinsic and thus allows
imaging of intact tissues or living organisms without labeling;
nonlinear excitation enables optical sectioning, and allows use of
near infrared excitation to minimize autofluorescence background;
photochemical damage of samples is minimized as SHG is a non-
resonant process that involves no absorption [16,17,18,19,20,21].
SHG imaging has been employed to observe structural proteins
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tendons, cartridges, dermis and fish scales [22,23,24,25,26,27],
and thick myosin filaments in myocytes [28,29,30,31,32].
Fundamental or applied clinical research inevitably involves
employment of animals at some stage. The zebrafish (Danio rerio)i s
a genetically accessible organism that possesses a muscular system
rapidly developing relative to higher vertebrates such as rodents;
the muscle proteins, structure, function and development of
zebrafish exhibit extensive homologies with that of humans; its
muscular development is visible or readily accessible in vivo at all
stages [33,34]. These unique properties render the zebrafish an
exceptionally attractive model to assess muscular diseases and the
myotoxicity of drugs in vivo with optical microscopy
[35,36,37,38,39,40]. Despite these advantages, little investigation
of myotoxicity induced by statin using the zebrafish has occurred.
Histological assessment performed in these tests was limited to
only specimens that had undergone extensive preparation
including fixation, sectioning and staining. The results of structural
examination were derived mostly from gross morphological
alteration as microscopes with poor spatial resolution were
employed, thus missing microstructural information [11,41,42].
As sample preparation might distort the fine structure of samples,
the results based on the structural modification observed from
histological specimens should be interpreted with caution [43]. No
quantitative assessment of statin-induced myopathy in vivo,
especially on the microstructural modification of sarcomeres, is
reported.
Here we describe the use of a SHG microscope to assess the
myotoxicity of statins in zebrafish. In contrast to conventional
histological imaging, observation of the muscle fibers in vivo
eliminates concern about undesirable structural distortion caused
by sample preparation. Analysis of SHG images at high resolution
further allows an accurate measurement of the length of
sarcomeres, the fundamental contractile unit of myocytes. We
demonstrate that statin caused a significant shortening of the
sarcomeres of zebrafish muscles while the morphological integrity
of the myocyte remained largely intact. This microstructural
abnormality is attributed to demolition of the thick myosin
filament in sarcomeres, and is associated with the biosynthetic
pathway of cholesterol or, specifically, the impaired production of
mevalonate by statins. This sarcomeric microstructural disorder
exhibited a strong correlation with the dosage and the duration of
treatment, a result that indicates a possibility to assess the severity
or the symptoms of muscle injury based on the altered length of
the sarcomere. In contrast to a conventional assessment of muscle
injury using clinical biomarkers in blood, such as creatine kinase
that is released from only disrupted myocytes, the ability to
determine subtle but unambiguous microstructural modification of
sarcomeres allows a diagnosis of muscle injury before an onset of
conventional clinical symptoms. In light of the increasing
prevalence of the incidence of skeletal muscle injury caused by
new therapies, our approach consolidates the combined use of
zebrafish and SHG imaging as an effective, rapid and sensitive
means to evaluate the safety profile of new therapies on vertebrates
in vivo.
Results
SHG Imaging Enables Microstructural Analysis of
Sarcomeres In Vivo and Observation of Myofibrillogenesis
in Zebrafish
The myocyte is composed of bundles of myofibrils that contain
myofilaments. The thick myosin myofilaments, thin actin
myofilaments and titin myofilaments assemble into specific
repeating organizations termed sarcomeres that represent the
basic contractile unit of the myocyte. Figure 1A is a cartoon
illustration of a sarcomere. As indicated in the cartoon, the length
of the sarcomere is defined as the separation between two z-disks.
According to the sliding-filament theory of muscle contraction, the
thin and thick filaments slide across each other during contraction
of the sarcomere, resulting in an increased overlap of the two
filaments and thus a shortened sarcomere. Figure 1B is a
representative SHG image of skeletal muscles measured on a living
zebrafish larva (3 dpf). The apparatus of the SHG microscope has
been described elsewhere [21,44]. The regions producing intense
SHG signals correspond to the location of thick myosin filaments
that arrange in equally spaced arrays in sarcomeres as illustrated in
Figure 1A [28]. Consistent with the literature [30], two distinct
patterns in the image are denoted as double band (gray arrow) and
single band (white arrow), respectively, in conformity with
convention. Figures 1C and 1D shows cross-sectional plots of
the double and single bands, respectively, in which the two dashed
lines correspond to the location of z-disks; their separation defines
the length of the sarcomere.
Although the origin of the two characteristic patterns exhibited
in the SHG image of skeletal muscles has been systematically
explored [30], whether the double and single bands shown in the
SHG image of zebrafish muscles convey identical sarcomere
lengths remains uncertain. To address this question, we performed
a systematic analysis of the length of the sarcomere determined
from both single and double bands. As shown in Figure 1E, the
sarcomeres of zebrafish muscles determined from either pattern
have indistinguishable lengths (1.8660.15 mm vs 1.8660.12 mm,
P=0.970). Our reported length is accordingly an average
determined from randomly selected regions of the image
regardless of either specific pattern unless explicitly specified.
Conventional microstructural analysis of biological tissues is
commonly achieved through histological examination with an
optical or electron microscope. Distortion of the specimens due to
sample preparation is almost inevitable, and might hinder a
quantitative structural analysis of tissues. In contrast, observation
of living zebrafish with a SHG microscope allows a microstructural
analysis of muscle sarcomeres free of distortion. We compared the
length of the sarcomeres of living zebrafish with that of zebrafish
fixed with paraformaldehyde, a procedure commonly employed in
conventional histological analysis. As clearly shown in Figure 2A,
the sarcomere of the fixed zebrafish is consistently shorter than
that of living fish (head, 1.7260.08 mm vs 1.9060.12 mm,
P=4.81610
27; tail, 1.7160.04 mm vs 1.9360.13 mm,
P=4.07610
28). This result confirms that fixation of the specimen
distorted the microstructure of sarcomeres, and specifically,
yielded an erroneously decreased length of the sarcomere.
After demonstrating that a SHG microscope enabled measure-
ment of the length of the sarcomere of zebrafish with superior
accuracy through eliminating concerns about structural distortion
due to sample preparation, we employed SHG imaging to
examine living zebrafish at various developmental stages.
Figure 2B displays representative SHG images of living zebrafish
measured at three representative timings (24, 36 and 72 hpf).
Comprehensive analysis of the length of the sarcomere in somites
near the head and the length near the tail at multiple
developmental stages are shown in Figure 2C. As shown there,
the sarcomere in somites near the head developed to its full length
(,1.9 mm) as early as 24 hpf. In contrast, the development of
sarcomeres in somites near the tail was retarded relative to that
near the head; the length of the sarcomere increased from
0.9960.17 mm at 24 hpf, to 1.6660.08 mm at 30 hpf, and finally
to its full length, 1.9360.09 mm, at 36 hpf. In subsequent
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untreated zebrafish at various stages served also as the control
for comparison with the length determined from treated zebrafish.
Statin Causes a Grossly Altered Morphology and
Microstructural Disorder of Sarcomeres of Zebrafish
Muscles
Representative SHG images of the control (untreated zebrafish)
and the treated zebrafish (50 mM) are displayed in Figures 3A
and 3B, respectively. The two images exhibit subtle but clearly
discernible morphological variation; specifically, the zebrafish
treated with statin developed with misorientation, displacement,
skewing, or contortion of the muscle fibers.
The SHG images shown in Figure 3A and 3B demonstrate
that the treatment of zebrafish larvae with statin induced grossly
morphological modification of the muscles, an observation
consistent with that reported from the use of immunoimaging,
but the latter poorly resolved images allowed only a qualitative and
subjective description, rather than a quantitative and objective
assessment of the structural alteration. To assess quantitatively the
structural alteration associated with myopathy, particularly the
sarcomeric distortion induced by the treatment with statin, we
analyzed the length of the sarcomere with high-resolution SHG
images.
We first examined underdeveloped zebrafish (24 hpf), and
display the result in Figure 3C. The treatment of zebrafish larvae
with statin (0.5 mM) for 12 h caused a significant shortening of the
sarcomere relative to the untreated control. The sarcomeres at
somites near the head and those near the tail exhibited a similarly
decreased length (head, 1.7360.09 mm vs 1.9160.08 mm,
P=1 610
28; tail, 1.7360.09 mm vs 1.9360.13 mm, P=
4.08610
29).
As the above experiments were performed on zebrafish larvae
(24 hpf) of which the sarcomeres at somites near the tail had not
developed to their full length, it is possible that the shortening was
due to arrested development of the sarcomeres caused by the
treatment. To clarify the cause, we performed complementary
measurements on zebrafish (72 hpf) with sarcomeres of fully
developed length, and display the result in Figure 3D. Similar to
the result shown in Figure 3C, the treatment of statin yielded also
significantly shortened 72-hpf zebrafish larvae (1.7260.15 mmv s
1.9060.12 mm, P=7.08610
27) relative to the control. As the
treatment yielded a similarly shortened sarcomere of zebrafish of
which the sarcomeres had already fully developed at the time of
treatment, the mechanism of arrested growth of sarcomeres is
excluded as the major cause of the sarcomeric abnormality at least
for zebrafish with fully grown sarcomeres.
Two other mechanisms might account for the shortening of the
sarcomeres. One mechanism is contraction of the sarcomere
induced by drugs. According to the sliding-filament theory of
muscle contraction, the sliding of the thin and thick filaments
results in an increased overlap of the two, thus shortening the
sarcomere during contraction. The other mechanism that might
explain the decreased length is demolition of the constituent
elements of the sarcomere induced by the drug, for example the
Figure 1. Sarcomeric length determined with SHG imaging. (A) A cartoon illustration of a sarcomere and the architectural arrangement of its
major constituent filaments. The length of a sarcomere is defined as the separation between two z-disks. (B) A high-resolution SHG image of zebrafish
muscles. The image exhibits two characteristic patterns that are denoted as double (gray arrow) and single bands (white arrow), respectively. Scale
bar: 5 mm. (C, D) Representative cross-sectional plots of a double band (C) and a single band (D). The length of the sarcomere was determined from
the distance between the two dashed lines as shown in the two cross-sectional plots. (E) Comparison of the averaged length of the sarcomere
determined from the two sarcomeric patterns. The statistics were calculated based on 12 images obtained from somites near the head (fifth to eighth
somite) of three 72-hpf zebrafish.
doi:10.1371/journal.pone.0024764.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24764Figure 2. Sarcomeric length of living and fixed zebrafish, and developing larva at different stages. (A) Comparison of length of
sarcomeres determined from zebrafish living and fixed with paraformaldehyde. The SHG images used to measure the lengths were measured on
somites near the head (black, somites 5–8) and the tail (red, somites 21–24). The statistics were calculated based on 21 images obtained from three
72-hpf zebrafish. (B) Representative SHG images of zebrafish measured at three developmental stages (24, 36 and 72 hpf). The images were measured
on regions near the head (somites 5,8) and the tail (somites 21–24). (C) Growth of the sarcomere from 1 to 12 dpf. The SHG images used to evaluate
the length were measured on somites near the head (black, somites 5,8) and the tail (red, somites 21–24). The statistics were calculated based on 21
images obtained from three 72-hpf zebrafish.
doi:10.1371/journal.pone.0024764.g002
Figure 3. Structural modification of zebrafish muscles induced on treatment with statin. (A) A representative SHG image of the control
(an untreated zebrafish larva, 72 hpf). (B) A representative SHG image of a zebrafish larva (72 hpf) subject to treatment with statin (50 mM) for 12 h.
Image size: 140 mm (w)6100 mm (h). (C) Effect of statin treatment on zebrafish with underdeveloped sarcomeres. The zebrafish was subject to a
treatment of statin (0.5 mM) at 24 hpf for 12 h, and imaged at 36 hpf (black: somites 5,8; red: somites 21–24). (D) Effect of statin treatment on
zebrafish with fully developed sarcomeres. The zebrafish was subject to a treatment of the same dosage at 72 hpf for 12 h, and the image was taken
at 84 hpf (head, somites 5,8).
doi:10.1371/journal.pone.0024764.g003
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define the mechanism.
As the SHG signal was produced specifically from the thick
myosin filament in the sarcomere, analysis of the separation of the
two maxima in the double band (hereafter termed the bare length)
and the full width at half maximum (FWHM) of the single band
(see also Figures 1C and 1D) would provide structural clues to
the integrity of the thick myosin filament. The cartoons displayed
in Figures 4A and 4B illustrate the expected modifications of the
three microstructural parameters (the length of the sarcomere,
FWHM and bare length) for sarcomeres subject to normal
contraction or to myosin demolition, respectively. The observation
of shortened sarcomeres with intact FWHM and bare lengths
would accordingly indicate contracted sarcomeres; in contrast, a
concomitant decrease of the three parameters would indicate
demolition of the thick myosin filament.
As a test of this hypothesis, we induced persistent contraction of
muscle with a treatment of caffeine (8 mM). As shown in
Figure 4C, 4D and 4E, the treatment caused a significantly
shortened sarcomere (1.7260.10 mm vs 1.9060.12 mm,
P=3.78610
25) while leaving the FWHM and the bare length
intact relative to the untreated control (the FWHM,
0.9760.08 mm vs 0.9860.05 mm, P=0.690; the bare length,
0.8160.10 mm vs 0.8160.05 mm, P=0.970). These observations
are consistent with results expected from the sliding-filament
theory of muscle contraction (Figure 4A).
Most significantly, analysis of the microstructural parameters for
zebrafish treated with statin showed that, in addition to the
shortened sarcomere shown before, the FWHM and the bare
length also exhibited an appreciable decrease after treatment with
statin (sarcomere length, 1.3960.05 mm vs 1.9060.12 mm,
P=3.15610
27; FWHM, 0.7560.07 mm vs 0.9860.05 mm,
P=2.52610
28; bare length, 0.6060.07 mm vs 0.8160.05 mm,
P=2.20610
24). With these results taken together, a detailed
analysis of the microstructure of the muscle sarcomere provides
unambiguous evidence that the treatment with statin caused
demolition of the thick myosin filament, and impaired integrity of
the sarcomere, which were manifested as shortened sarcomeres.
Statin-induced Sarcomeric Disorder Observed with SHG
Imaging Is Associated with an Impaired Production of
Mevalonate in the Biosynthetic Pathway of Cholesterol
The myotoxicity of statin was suggested to be attributed to the
effective inhibition of HMG CoA reductase by statins, resulting in
Figure 4. Shortened sarcomeres caused by demolition of the myosin filament. (A) A sarcomere subject to normal contraction. (B) A
sarcomere subject to demolition of the myosin filament (B). (C, D, E) Comparison of sarcomeric microstructures of zebrafish subject to no treatment
(the control), a treatment of statin (50 mm) at 72 hpf for 120 h, and that of caffeine (8 mM) at 72 hpf for 3 h. All images were obtained at the end of
treatments on regions between somites 5,8. (C) Sarcomere length. The statistics were calculated based on 21 SHG images obtained from three
zebrafish. (D) Full width at half maximum (FWHM) of the single band. The statistics were calculated based on 15 SHG images obtained from three
zebrafish. (E) Bare length of the double band. The statistics were calculated based on six images obtained from three zebrafish. The FWHM and the
bare length were determined on analysis of cross-sectional plots of the single and double bands, respectively, as illustrated in the insets of (D) and (E).
doi:10.1371/journal.pone.0024764.g004
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such as mevalonate, which is an important precursor of cholesterol
in the biosynthetic pathway of cholesterol [45]. Other workers
showed that an addition of mevalonate can rescue the morpho-
logical damage of muscles caused by statin [11].
We have shown that the treatment of statin to zebrafish larval
resulted in a significantly shortened sarcomere. To provide
unambiguous mechanistic evidence that the microstructural
alteration of sarcomeres observed with SHG imaging in living
zebrafish is associated also with the biosynthetic pathway of
cholesterol, and, specifically, with an impaired production of
mevalonate rather than a nonspecific effect, we performed
rescuing experiments by co-treating zebrafish (24 hpf) with
mevalonate (100 mM) and statin (0.5 mM) for 12 h. The result
displayed in Figure 5 clearly shows that this co-treatment
completely prevented the shortening of sarcomere caused by the
treatment with statin alone. This result confirms that the observed
microstructural alterations of sarcomeres are due also to the
inhibition of HMG CoA reductase or the biosynthetic pathway of
cholesterol with statins, and, specifically, through an impaired
production of mevalonate, rather than a nonspecific effect.
The Severity of Statin-induced Myopathy Is Correlated
with Altered Length of Sarcomere
To demonstrate that SHG images of muscle sarcomeres enables
assessment of the severity of myopathy induced by statin, we
induced myopathy of varied severity on treating zebrafish with
statin of varied dosage and duration, and evaluated whether the
altered length of the sarcomere exhibited a correlation with dosage
and duration of treatment.
We first assessed the dosage dependence on treating zebrafish
larvae (72 hpf) with statin of three dosages (0.05, 0.5 and 50 mM)
while maintaining a constant duration (12 h) of treatment. The
results, summarized in Figure 6, show that the shortening of
sarcomeres exhibited a strong dependence on dosages: the length
decreased to 1.78, 1.72 and 1.53 mm from 1.90 mm (untreated
control measured at 84 hpf), or 6%, 9% and 21% decrease relative
to the control, for dosage 0.05, 0.5 and 50 mM, respectively. The
strong correlation of the shortening of sarcomere with dosage
indicates that a microstructural analysis of muscle sarcomeres with
SHG images allows a quantitative assessment of the severity of
myopathy induced by statin.
To consolidate this point, we evaluated the dependence of
duration on treating the zebrafish for a duration 120 h for each
designated dosage. The results, incorporated in the same figure,
show that the sarcomeres exhibited a consistently greater
shortening with duration of treatment increasing from 12 h to
120 h for each tested dosage. The prolonged treatment (120 h)
caused a shortening of the sarcomere increased by 8%, 15% and
27% relative to treatment for 12 h and dosages 0.05, 0.5 and
50 mM, respectively. This result demonstrates the capability of
SHG microstructural analysis of muscle sarcomeres to assess the
severity of myopathy induced by statin.
Discussion
With a SHG microscope, we have determined the length of
sarcomere of zebrafish larvae in vivo at various developmental
stages. Our results, consistent with those reported in the literature
[46], indicate that one can observe the myofibrillogenesis of
zebrafish in vivo without employing labeling reagents as required
for immunoimaging. We show also that the length of sarcomeres
determined from zebrafish fixed with paraformaldehyde consis-
tently exhibited values erroneously smaller than those determined
from living zebrafish. This result demonstrates that SHG images of
objects in vivo can provide an accurate measurement of the length
of growing sarcomeres while eliminating concern about possible
structural distortion caused by sample preparation.
The treatment with statin caused demolition of the myosin
filament in zebrafish larvae caused significantly shortened
sarcomeres of skeletal muscles. With rescue experiments, we
provide mechanistic evidence that the microstructural abnormality
observed with SHG imaging is associated with an inhibited
Figure 5. Rescuing effect of mevalonate on the shortened
sarcomere induced with statin. Left: the control, untreated
zebrafish; middle: zebrafish subject to a treatment of statin (0.5 mM)
at 24 hpf for 12 h; right: zebrafish subject to a co-treatment of statin
(0.5 mM) and mevalonate (100 mM) at 24 hpf for 12 h. All SHG images
used to determine the sarcomere length were measured at 36 hpf on
somites near the head (black, somites 5,8) and the tail (red, somites
21–24). The two images displayed as insets are representative results of
co-treatment measured near the head (left) and the tail (right),
respectively. Image size: 50650 mm. The statistics were calculated
based on 21 images obtained from three zebrafish.
doi:10.1371/journal.pone.0024764.g005
Figure 6. Dependence of the sarcomeric length on the dosage
and the duration of treatment. The zebrafish was treated with
concentrations 0.05, 0.5 and 50 mM at 72 hpf for either 12 h (red) or
120 h (black). The images were obtained at the end of the treatments
on regions between somites 5,8. The statistics were calculated based
on 21 images obtained from three zebrafish.
doi:10.1371/journal.pone.0024764.g006
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caused by statin. Such an association of shortened sarcomeres with
deleterious muscle manifestations induced by statin is unreported.
As the muscle proteins, structure, function and development of
zebrafish exhibit extensive homologies with those of humans
[33,34,38,47,48], this finding has clinical significance. As the
myosin filament a constituent filament in the sarcomere that is the
fundamental contractile unit of muscle fibers, the demolition of the
myosin filament might result in impaired muscular functions that
translate into clinical symptoms of myopathy.
The severity of the clinical symptoms of myopathy has been
shown to depend on the dosage and the duration of treatment with
statin [10]. This work shows that the microstructural distortion of
sarcomeres, specifically the altered length of sarcomeres, exhibited
also a strong correlation with the dosage and the duration of the
treatment. This finding might allow an assessment of the severity
of myopathy through microstructural analysis of sarcomeres with a
SHG microscope. Relative to clinical symptoms of myopathy that
have been difficult to evaluate and can be subjective from patient
to patient, a microstructural analysis of the sarcomere with SHG
might serve as a reliable and objective index for assessment of the
severity of myopathy. In light of the increasing prevalence in the
incidence of muscle injuries caused by new therapies, SHG
imaging combined with the zebrafish models of varied muscular
diseases can be particularly useful for an exploration of the
pathogenesis of muscle diseases and for the development of
effective therapies against these diseases.
In a clinical setting, myopathy is generally diagnosed according
to an elevated circulating level of creatine phosphokinase (CPK)
that is released from disrupted myocytes, but this enzyme is
unstable such that its circulating level in blood can be apparently
lost before blood sampling. The use of CPK as a reliable
biomarker of muscle diseases has consequently been questioned
[12,13]. Further, this biomarker does not invariably correlate with
clinical symptoms of myopathy because an elevated CPK value
can be associated with various diseases. A determination of the
subtle sarcomeric change associated with myopathy might allow a
diagnosis of myopathy before an occurrence of symptoms such as
elevated CPK levels.
Materials and Methods
The Animal Investigation Committee of National Chiao Tung
University approved this work (Permit Number: 0099000).
Reagents
Paraformaldehyde, tricane, mevalonate and lavastatin (Sigma
Aldrich) and caffeine (Alfa Aesar) were obtained from the
indicated sources.
Animals
Breeding colonies of AB strain zebrafish (Danio rerio) were
purchased (Taikong Co., Taiwan) and were kept in small aquaria
according to protocols described in the literature [49]. In brief, they
were kept in water at 28uC and subject to cycles with light for 14 h
and darkness for 10 h. Embryos were generated by natural pair-
wise mating. Spawning occurred when the light was just turned on
and eggs were collected 30 min afterwards. The collected eggs were
further incubated in a flask until subsequent experiments. Zebrafish
were staged by hours post fertilization (hpf) and days post
fertilization (dpf). At 1 dpf, eggs were examined under a stereo-
microscope. Dead or unfertilized eggs were removed.
Treatment of Zebrafish
A solution of statin or caffeine or mevalonate was prepared on
dissolving the reagent in water from the fish tank. The zebrafish
were treated on adding the solution to the flask that contained
zebrafish at a designed time and for a designed duration, according
to experiments. Untreated zebrafish served as the control. Before
imaging, the zebrafish were anesthetized with tricane (150 mg/L).
Apparatus
The apparatus was modified from our home-built multiphoton-
imaging system reported elsewhere [21,44]. A pulsed near-infrared
laser (1064 nm, 7 ps, 76 MHz; PicoTran, High-Q Laser, Austria)
served for excitation. The pulse train of the laser was directed to
an inverted optical microscope (Eclipse Ti, Nikon, Japan) and
focused onto the sample with a water immersion objective (CFI
Plan Apo 60X, N.A. 1.2, Nikon, Japan). To eliminate the
polarization dependence of the SHG signal, the laser light was
converted to circularly polarized before entering the microscope.
The forward propagating signal was collected with a microscope
condenser (N.A. 0.52), spectrally filtered with optical filters, and
detected with a thermoelectrically cooled photomultiplier sensor
(H-7422-40, Hamamatsu, Japan). Generation of the second-
harmonic signal was confirmed with spectral analysis of the
emission that exhibits a single spectral line at 532 nm. To increase
the ratio of signal to noise, a lock-in amplifier was employed; the
SHG images were constructed on recording the demodulated
signal in a manner point by point while raster-scanning the sample
with respect to the fixed laser focus using a three-axis scanning
stage (P-563.3CD, Physik Instruments, Germany) as described
before [21,44]. The laser power, measured at the focus, was
typically between 40 and 60 mW. The temporal duration at each
pixel was 10 ms. Sample scan, signal collection and image
construction were implemented with computer codes (LabView,
National Instruments, USA).
Statistical Methods
The means of two groups were compared with the two-tailed
Student’s t test. The levels of statistical significance were set at
P,0.05, P,0.01, and P,0.001, respectively.
Conclusions
We found that statin caused significantly shortened sarcomeres
and the sarcomeric disorder is associated with the biosynthetic
pathway of cholesterol impaired by statin. The result indicates the
possibility to assess the severity of myopathy and holds a promise
for an early diagnosis of myopathy with SHG microstructural
analysis of sarcomeres. This approach is extensible to evaluate the
safety profile of new therapeutic targets.
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